Monitor pre-existing and drug-related antibody and T cell responses for immune adverse effect risk assessment. We provide the fingerprint immunogenicity analysis of your antibody or protein drug in a single assay with epitope mapping technology, including T cell services to determine the presence of mAb-reactive T cells in patient PBMCs by ELISpot. This dual strategy enables comparison of the immune landscape among patients with and without adverse effects.